XML 33 R11.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
REVENUES FROM CONTRACTS WITH CUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2022:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2022$11,412 
Transferred to trade receivable from contract asset included
     in beginning of the year contract asset 		(11,412)
Contract asset, net of transferred to trade receivables on contracts during the period10,122 
Contract asset, December 31, 2022$10,122 
Contract Liability
Contract liability, January 1, 2022$11,946 
Recognition of revenue included in beginning of year contract liability(5,349)
Contract liability, net of revenue recognized on contracts during the period9,596 
Foreign currency translation(66)
Contract liability, December 31, 2022$16,127 
At December 31, 2022, the short-term portion of the contract liability of $7.3 million and the long-term portion of $8.8 million is included in current liabilities and other liabilities, respectively, in the consolidated balance sheet.
As of December 31, 2022, the Company is expected to recognize revenue of approximately $7.3 million in 2023, $4.2 million in 2024, $2.7 million in 2025, $1.1 million in 2026, $0.7 million in 2027, and $0.1 million thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2022, 2021 and 2020 (dollar amounts in thousands):
Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Neurosurgery$794,017 $802,959 $716,339 
Instruments225,547 222,273 178,492 
Total Codman Specialty Surgical1,019,564 1,025,232 894,831 
Wound Reconstruction and Care(2)(3)
406,689 392,463 293,038 
Extremity Orthopedics(1)
— — 78,316 
Private Label131,413 124,753 105,683 
Total Tissue Technologies538,102 517,216 477,037 
Total revenue$1,557,666 $1,542,448 $1,371,868 
(1) On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. See Note 4, Acquisitions and Divestitures, for details
(2) See Note 4. Acquisitions and Divestitures, for details around the ACell acquisition.
(3) On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note 4, Acquisitions and Divestitures
See Note 16, Segment and Geographical Information, for details of revenues based on the location of the customer.